Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anxiety
Biotech
Vanda pauses social anxiety program after failing phase 3 trial
A phase 3 trial of Vanda’s social anxiety disorder drug candidate has missed its primary endpoint, prompting the company to put the program on hold.
Nick Paul Taylor
Oct 15, 2026 2:25am
Definium LSD drug goes 3 for 3 with another pivotal trial win
Sep 14, 2026 7:00am
Definium hits another ph. 3 homerun with anxiety ‘sea change’
Aug 12, 2026 7:00am
Double shot of Vistagen’s anxiety nasal spray misses in ph. 2
Aug 6, 2026 10:32am
Vistagen fails another phase 3 anxiety trial, spies path forward
Jun 30, 2026 9:48am
Otsuka posts phase 3b ADHD trial win ahead of looming FDA ruling
Jun 25, 2026 9:13am